Navigation Links
MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
Date:11/7/2007

tory approvals, (8) successfully conduct clinical trials in a timely manner, (9) establish its competitive position for its products, (10) develop and commercialize products that are superior to existing or newly developed competitor products, (11) develop products without any defects, (12) have sufficient capital resources to fund its operations, (13) protect its intellectual property rights and patents, (14) implement its sales and marketing strategy, (15) successfully attract and retain collaborative partners, (16) successfully commercialize and gain market acceptance for its Keflex products, (17) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (18) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)... Communications announces a highly effective and u... struggling to make an economic recovery. , ...u fears is the type of challenge that could send a...ng to Dr. David Benton, business growth expert and...em – The Rfactor Intensive . “Fear ...
(Date:11/25/2009).../PRNewswire/-SentinelleMedicalInc.,aleadingmanufac...reandCalgaryScientificInc.,aleadingproviderofsoftw...fAegis(TM)Breast4DAdvancedVisualizationsoftware. ,...otprintWebclientbasedmedicalimagingofferinginthema...orzero-footprintaccess-requiringnosoftwaredownload...
(Date:11/25/2009)...wswire/--TheBayAreaAirQualityManagementDistrictisi...ir Alert forThursday,November26,2009whichbans...l,bothindoorsandoutdoors. ,, "Cold,stillweather...ackBroadbent,executiveofficeroftheAirDistrict."We,...eighborsandfellowcommunitymembersthisThanksgiving,...
(Date:11/25/2009)...ssure? This simple question has been the focus of...ted gene Modulates High Blood Pressure in Mice & M...mple question has been the focus of intense resear...irst time established a link between a novel gene,...ess in mice as well as humans. The studies were di...
(Date:11/25/2009)...logical symptoms, study finds , , WEDNE...e effects are among the potential problems faced b...e treated with cisplatin-based chemotherapy, a new...rwegian men treated for unilateral testicular canc...-up survey conducted from 1998 to 2002. , The r...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:New stress-related gene modulates high blood pressure in mice and men 2
... British study says that Man's best friend might b...tionally sensitive noses, // dogs can smell odors ...gs of varying breeds and ages were trained over se...m six control group participants and one bladder c...
...vention program designed to educate parents about ...toms of asthma in children // say researchers .M...e children were allergic to at least one indoor en...nately high rate. Researchers designed an inter...
...sillectomy is a common procedure in children , eve...ses with milder symptoms.// A new study suggests t...tonsils and adenoids in children with mild throat ... had the surgery, and half were allocated to watch...
...ers from several international centers combined ef...educing risk factors for disease. They looked at 2..., alcohol use, unsafe water, sanitation and hygien...d the world in 2000 resulted from a combination of...
...y, lung cancer is the leading cause of cancer deat...search shows women // have double the risk of deve...searchers in New York studied nearly 3,000 men and...bability of developing lung cancer. To best determ...
...udy confirms the recommendation by the American He... water-soluble fiber,// is beneficial to your hear...between dietary fiber intake and the reduction of ...disease and cardiovascular disease. The study i...
Other Medicine News:Health News:High Fiber Diet Found To Protect The Heart 2
(Date:11/25/2009)...Newswire/--BioTrendsResearchGroup,Inc.releasedWave...rstinamulti-phasesyndicatedmarketresearchprojecttr...omproductlaunchthroughthefirstsixmonthsofavailabil...tionfrom75uniqueDermatologistsandqualitativeinform...Stelara,obstaclestouse,typicalpatienttypes,product...
(Date:11/25/2009)...ov.25/PRNewswire/--RegadoBiosciences,aprivatelyhel...erswithactivecontrolagents,announcedthatDavidMazzo...fray21stAnnualHealthCareConferenceattheNewYorkPala...ivenat1:10pm(EST)onTuesday,December1andwillinclude...eaddevelopmentprogram,theanticoagulantsystem,REG1....
(Date:11/25/2009)...Nov.25/PRNewswire/--SwissrayInternational,Inc.alea...ystems,announcedtodaythatitsoperationshavebeenacqu...sgrowingSwissray,smedicalimagingbrand.Theacquisiti...scontractsandinventory.After25yearsofsuccessandgro...logicaladvancementswithstableandsteadygrowth. ,...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Swissray International Announces New Ownership 2Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 53427 1Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 53427 2Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 53427 3John Legend and Gap Join 28PRODUCT 29RED 28TM 29 to Help Eliminate AIDS in Africa with Exclusive 28RED 29ZONE Seating at Madison Square Garden 4807 1John Legend and Gap Join 28PRODUCT 29RED 28TM 29 to Help Eliminate AIDS in Africa with Exclusive 28RED 29ZONE Seating at Madison Square Garden 4807 2John Legend and Gap Join 28PRODUCT 29RED 28TM 29 to Help Eliminate AIDS in Africa with Exclusive 28RED 29ZONE Seating at Madison Square Garden 4807 3Online H1N1 Management 3A FairChoice Helps Schools Respond to Infectious Disease on Campus 4806 1Online H1N1 Management 3A FairChoice Helps Schools Respond to Infectious Disease on Campus 4806 2
...9, 2007 /PRNewswire-FirstCall/ - YM,BioSciences In...,and commercializes differentiated products for pa...sented by investigators from Kinki,University Scho...eting of The Japanese Association for Molecular Ta...nstrated the increased,radiosensitivity of human N...
...INESS WIRE)--July 9, 2007 - NexMed, Inc.,(NASDAQ: ...ments,based on the NexACT(R) drug delivery technol...ompleted patient enrollment for Phase,III clinical...homycosis (nail fungus). Pursuant to the terms of ... be entitled to a milestone,payment early next yea...
Other Medicine Technology:YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 2YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 3YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 4NexMed Announces Completion of Patient Enrollment in Two Pivotal,Phase 3 Studies for Anti-Fungal Product 2
Ovation BioNatural Pipette, one-stroke, fixed volume, 200L
Finnpipette Fixed Volume, 200ul
Pipetman F100
Eppendorf Research Series 2100 Fixed-volume Pipette, 100 l
Medicine Products: